Long‐term outcome of high‐grade encapsulated papillary carcinoma of the breast: implications for staging and management
Histopathology · 2026-12 · 89 (6) · 941-953
DOI: 10.1111/his.70240 ↗Abstract
Background Encapsulated papillary carcinoma (EPC) of the breast is an uncommon tumour with controversial biological behaviour and staging. Emerging evidence suggests that EPC with adverse pathological features (EPC‐A) may exhibit invasive potential. The absence of uniform staging criteria contributes to management variability. This study evaluates the clinicopathological characteristics and clinical course of high‐grade EPC (HG‐EPC), including EPC‐A. Materials and methods This retrospective multicentre study (2000–2025) included 25 HG‐EPC cases, irrespectively of ER/PR and HER2 status. Tumours with frank stromal invasion beyond microinvasive foci were excluded. Histopathological re‐evaluation was performed in accordance with 2019 WHO classification criteria. Results Of 38 cases reviewed, 25 fulfilled the inclusion criteria as EPC (mean age 57.2 years, mean tumour size 2.9 cm). Six cases (24%) demonstrated conventional‐type microinvasive components. A subset of 16 cases fulfilled criteria for EPC‐A, defined by high‐grade morphology in combination with ER/PR‐negative (or ER
EUVIMED